Skip to Content Skip to Search

Pricing and access strategies

We want our medicines and vaccines to be accessible to everyone who needs them, no matter where they live. We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Our ranking as top of the Access to Medicines Index (ATMI) reflects the strength of our long-term, global commitment to improving access to healthcare. The Index, published every two years, gives an independent assessment of pharmaceutical companies’ efforts to improve access. We have consistently ranked top since it began in 2008.


The pricing of pharmaceutical medicines and vaccines is an important topic in both developed and developing countries. We understand payer and patient concerns about the affordability of healthcare and are leading efforts to develop sustainable solutions.

We develop pricing strategies based on country-specific circumstances, such as patient affordability, the local healthcare system and other social and economic factors. When setting the price of our medicines in developed markets, we apply a value-based approach to balance reward for innovation with access and affordability. We price our medicines according to the value and outcomes they bring to patients, providers and payers while being sensitive to market and societal expectations.

In developing countries, we use innovative pricing structures as part of our access strategies to extend product reach. We also do not file patents for our medicines in the least developed countries (LDCs) and low-income countries, and do not enforce historic patents that we have in those countries. This allows generic companies to manufacture and supply generic versions of GSK medicines in those countries. 

Access to Vaccines

We are a long-standing partner of Gavi, the Vaccine Alliance, which funds immunisation programmes for some of the world’s poorest countries. Gavi-eligible countries always get our lowest prices, which can be as little as one-tenth of those for developed nations. Gavi supports countries with a GNI per head of less than $1,630. In 2020, we supplied Synflorix, our pneumococcal vaccine, to eight Gavi-eligible countries and one former Gavi country, and our Rotarix vaccine, to protect against rotavirus, is available in 32 Gavi countries and four former Gavi countries.

As countries develop and exceed the Gavi GNI threshold, they ‘graduate’ from Gavi support. We have committed to provide Gavi with more than 850 million vaccine doses at reduced prices to help protect 300 million children in developing countries by 2024. And we are freezing our vaccine prices for graduating countries for ten years to help them maintain their commitment to immunisation during their transition. 

We are a long-standing supplier of oral polio vaccines to Unicef and have contributed billions of doses to the Global Polio Eradication Initiative since it was created in 1988.

Access to HIV medicines

Extending access to HIV treatment and care is a priority, particularly in low-income countries where nearly 90% of people affected by HIV live.

ViiV Healthcare’s voluntary licensing agreements with the Medicines Patent Pool and Aurobindo Pharma allow generic manufacturers to produce and sell low cost single or fixed dose combination products containing dolutegravir for adults and children in countries with the highest burden of HIV.

Eliminating lymphatic filariasis

We are an active partner in one of the world’s biggest and boldest public health initiatives, led by the WHO, to rid the world of lymphatic filariasis (LF). It is more commonly known as elephantiasis, a condition with marked hardening and thickening of the skin that frequently accompanies massive swelling in the arms, legs, breasts and genitals. The disease is transmitted by mosquitoes and has been one of the principal causes of permanent disability worldwide, affecting more than 120 million people in tropical and sub-tropical areas of Africa, Asia, the Pacific, the Middle East and the Americas.

Since 1999, we have donated over 10 billion tablets of albendazole as part of our commitment to working with partners to eliminate and control two neglected tropical diseases. One albendazole tablet can address both lymphatic filariasis (LF) and soil-transmitted helminthiasis (STH -intestinal worms). We are committed to continue donations of albendazole for LF until it has been eliminated as a public health problem worldwide, and we have extended our donation for STH in school age children through to 2025.

The little pill that could: one medicine taking on two neglected diseases

Since 1999 we have donated over ten billion albendazole tablets as part of the fight against two neglected tropical diseases that burden some of the very poorest communities.

Read more